Corcept Therapeutics Incorporated (CORT)
NEUTRALFundamental
58
Precio
$123.06
Capitalización Bursátil
$13.04B
Parte 1 · Cuánto vale la empresa
Resumen
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$831M
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$55M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$142M
Patrimonio Neto Total
$648M
Pasivo Total
$189M
Ratio de Liquidez
2.86
Cobertura de Intereses
-
Deuda/EBITDA
0.21
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$99.79
Precio Actual
$123.06
Margen de Seguridad
-23.3%
Rango de Valor Justo
$64.86 - $134.71
Métodos de Estimación
Métricas de Valoración
Ratio P/E
293.43
ROE
15.4%
Ratio P/B
18.88
P/FCF
124.60
Margen Bruto
98.3%
ROIC
0.7%
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
0.7%
WACC
8.0%
ROIC − WACC
-7.3 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Criterios de Análisis Fundamental
Superado (15)
- EPS shows upward trend
- Price CAGR 32.63%
- Gross Margin 98.3%
- Debt/Equity ratio
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 8.4%
- Revenue Growth 5Y 16.6%
- Analyst Consensus 83% Buy
- Earnings Surprise avg 1684.0%
- Earnings Quality (OCF/NI) 1.99
Fallido (9)
- ROIC 0.7%
- P/FCF 124.60
- P/B Ratio 18.88
- Operating Margin 0.8%
- Price below Graham Number
- DCF valuation (Overvalued)
- Share Dilution 5.9%
- Net Margin Trend 6.6% vs 18.7%
- Piotroski F-Score 4/9
No disponible (3)
- Dividend Payout NaN%
- Interest Coverage
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Señales mixtas: algunas áreas requieren atención
Calidad de los Beneficios
Alta calidad: beneficios respaldados por efectivo
Dilución de Acciones
Emitiendo nuevas acciones, diluyendo la participación
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Dr. Joseph K. Belanoff M.D. | Co-Founder, President, CEO & Director | 68 |
| Mr. Atabak Mokari | CFO & Treasurer | 48 |
| Mr. Sean Maduck | President of Endocrinology | 48 |
| Dr. William Guyer Pharm.D. | Chief Development Officer | 57 |
| Mr. Gary Charles Robb J.D. | Chief Business Officer & Secretary | 62 |
| Mr. Joseph Douglas Lyon | Chief Technology & Accounting Officer | 47 |
| Dr. Hazel Hunt Ph.D. | Chief Scientific Officer | 65 |
| Ms. Amy Flood | Chief Human Resources & Communications Officer | - |
| Ms. Monica Tellado | President of Emerging Markets | 52 |
| Mr. Roberto W. Vieira | President of Oncology | - |
Riesgo de Auditoría
8
Riesgo del Consejo
5
Riesgo de Compensación
7
Riesgo de Derechos del Accionista
7
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for CORT, sourced from Markets Gazette.